Efficacy And Safety Of Azacitidine (Aza) In Combination With The Anti-Pd-L1 Durvalumab (Durva) For The Front-Line Treatment Of Older Patients (Pts) With Acute Myeloid Leukemia (Aml) Who Are Unfit For Intensive Chemotherapy (Ic) And Pts With Higher-Risk Myelodysplastic Syndromes (Hr-Mds): Results From A Large, International, Randomized Phase 2 Study